EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)

Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Yizhe Chen iD, Yan Li, Yongjun Xue, Patrick Brown, Christopher Hernandez, Shelonitda Rose, Richard Pilot, Gopal Krishna, Ken Ogasawara iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70118 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yizhe Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Primary Myelofibrosis, Pyrrolidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Bristol Myers Squibb, Princeton, NJ, USA, Bristol Myers Squibb, Bristol-Myers Squibb Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Fedratinib is a potent, oral, Janus kinase inhibitor for the treatment of myelofibrosis (MF). This report describes exposure–response (E–R) analyses of fedratinib based on pooled data from phase 2/3 studies in patients with intermediate‐2 or high‐risk MF, with or without prior ruxolitinib exposure.

Methods

Pharmacokinetic (PK) exposures were derived from the population PK analysis. Efficacy endpoints included spleen volume reduction ≥35% (SVR35) and total symptom score reduction ≥50% (TSS response). Safety endpoints included grade ≥3 anaemia or thrombocytopenia, any‐grade nausea/vomiting and diarrhoea. The E–R models were developed using logistic regression analyses.

Results

Fedratinib exposure was positively associated with SVR35 (odds ratio [OR], 38.2; 95% confidence interval [CI], 12.4–118; P < 0.001) and TSS response (OR, 20.8; 95% CI, 6.27–69.2; P < 0.001), after adjusting for covariates. Baseline spleen volume was inversely associated with SVR35 ( P = 0.029). Prior ruxolitinib exposure was not associated with SVR35 ( P = 0.090) or TSS response ( P = 0.326). Although numerically higher incidence of adverse events was observed in patients with higher fedratinib exposure, there was no statistically significant association between fedratinib exposure and any safety related endpoints. Prior ruxolitinib exposure was associated with experiencing grade ≥3 thrombocytopenia ( P = 0.004). Lower baseline haemoglobin level (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsPrimary MyelofibrosisPyrrolidinesAdultAgedFemaleHumansMaleMiddle AgedAnemiaClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDose-Response Relationship, DrugNitrilesPyrazolesPyrimidinesSpleenThrombocytopeniaTreatment OutcomeBenzenesulfonamides

Stichwörter der Autor:innen

doseexposure–responsefedratinibmyelofibrosisprophylaxis

Substanzen

fedratinibJanus Kinase InhibitorsNitrilesPyrazolesPyrimidinesPyrrolidinesruxolitinibBenzenesulfonamides

Autor:innen und Institutionen

  • Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA.
  • Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
  • Worldwide Patient Safety, Bristol Myers Squibb, Princeton, NJ, USA.

ORCID-Profile: Yizhe Chen, Ken Ogasawara

Förderung

  • Bristol Myers Squibb, Princeton, NJ, USA
  • Bristol Myers Squibb
  • Bristol-Myers Squibb Canada

Zitieren

APA

Chen, Y., Li, Y., Xue, Y., Brown, P., Hernandez, C., Rose, S., Pilot, R., Krishna, G., & Ogasawara, K. (2025). Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70118

Vancouver

Chen Y, Li Y, Xue Y, Brown P, Hernandez C, Rose S, et al. Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70118

BibTeX
@article{Chen2025,
  author = {Chen, Yizhe and Li, Yan and Xue, Yongjun and Brown, Patrick and Hernandez, Christopher and Rose, Shelonitda and Pilot, Richard and Krishna, Gopal and Ogasawara, Ken},
  title = {Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70118}
}
Kostenlos starten →